Leg Edema Unveiled: The Uncommon Culprit of Follicular Lymphoma
DOI:
https://doi.org/10.53685/jshmdc.v4i2.214Keywords:
Follicular lymphoma, Malignancy, Non-Hodgkin’s lymphoma, B-cell neoplasm, Leg edema, SwellingAbstract
Follicular Lymphoma is a type of Non-Hodgkin's Lymphoma. It is defined as a lymphoma of germinal center B cells and a complex disease involving genetic and epigenetic mutations of Follicular B cell. Some of the commonly known alterations are cell in BCL-2 oncogene and somatically mutated genes. Follicular Lymphoma is the second most prevalent malignancy in the west accounting for about 10-20% of all lymphomas although an alarming rise has been seen in Pakistan as well. A lot of diagnostic challenges are being faced as this disease is indolent and presents atypical features. An effective treatment regime for follicular lymphoma fluctuates depending on the extent of disease and the medical history of the patient. Various methods are available for the risk assessment of the disease. Radiotherapy, rituximab monotherapy or combination therapy are the first line of treatment for restricted spread for follicular lymphoma. For aggressive stage of disease is managed with disease surveillance with imaging and rituximab is given in low grade tumors while chemotherapy and along with immunotherapy is the choice of treatment in high grade tumors. We report a patient here who presented with gross and progressing edema of the right lower limb that started in the foot and progressed proximally up to the thigh. Literature shows that unilateral lymphoedema could be an initial symptom of malignancy and is more common in woman than in males so must be sought as a potential diagnosis.
References
Brown JR, Freedman AS, Aster JC. Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma. UpToDate: Waltham, MA, USA. 2021.
Matasar MJ, Luminari S, Barr PM, Barta SK, Danilov AV, Hill BT, et al. Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs. The oncologist. 2019; 24(11): e1236-1250.
Freedman AS, Friedberg JW. Initial treatment of advanced stage (III/IV) follicular lymphoma. U: UpToDate, Post TW ur. UpToDate [Internet]. Waltham, MA: UpToDate. 2017.
Khanlari M, Chapman JR. Follicular lymphoma: updates for pathologists. J Pathol Transl Med. 2022; 56(1):1-15.doi:10.4132/jptm.2021.09.29
Bolognesi M, Bolognesi D. Unusual Presentation of Non-Hodgkin’s B-Cell Lymphoma with Unilateral Right Limb Lymphedema. Case Reports in Clinical Medicine. 2014; 3(11):577.doi:10.4236/crcm. 2014.311125
Freedman, A, Jacobsen, E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020; 95: 316-327. doi:10.1002/ajh.25696
Sajid T, Intisar-ul-Haq HI, Chaudhary AK. An obscure cause of leg edema, is non-Hodgkin's lymphoma. J Coll Physici Surg Pak: 2009; 19(4):254-256.
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997; 89(11): 3909-3918.
Dreyling M, Ghielmini M, Rule S, Salles G, Ladetto M, Tonino SH, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(3): 298-308.doi:10.1016/j.annonc.2020.11. 008
MacManus M, Fisher R, Roos D, O’Brien P, Macann A, Davis S, et al. Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03. J Clin Oncol. 2018;36(29): 2918-2925 .doi:10.1200/JCO.2018. 77.9892.
Probowati W, Astuti MP, Utomo BP, Hardiyanti MS, Purwanto I. Excellent response of rituximab and bendamustine in elderly patient with relapsed diffuse large B-cell lymphoma: a case report. J Med Sci. 2021; 53(1).doi.org/1019106/JMedSci005201202110
Jiang WQ, Huang HQ. Guidelines for the diagnosis and treatment of follicular lymphoma in China. Cancer Biol Med. 2013; 10(1):36-42.doi:10.7497/j.issn.2095-3941.2013. 01.006
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Syed Muhammad IbnE Ali Jaffari, Samaha Nisar, Narjis Malik, Syed Muhammad Aun Ali Jaffari, Omar Nisar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
-
Non Commercial — You may not use the material for commercial purposes.
-
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.